eMotiph: E-mental Health Solution for Patients With Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-01

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Therefore, the development of innovative evidence-based interventions adjunctive to pharmacological and psychological treatment are necessary for improving results in patients with treatment-resistant schizophrenia (TRS). Studies with digital solutions have shown feasibility, acceptability and even preliminary efficacy data. But no earlier published study has focused on TRS.

The eMOTIPH is an innovative solution addressed to TRS and born from the outcomes of the previous study eMOTIPH Part 1 (study of beliefs, needs, and limitations associated with current intervention in TRS patients).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia

NCT03064776

Schizophrenia

COMPLETED NA

Study of Intra- and Interpersonal Multimodal Synchronizations in a Social Interaction in Individuals with a Diagnosis of Schizophrenia.

NCT06484387

Schizophrenia

RECRUITING NA

Exploring the Effectiveness of Digital Anti-stigma Therapy on Illness Perception and Perceived Stigma in Patients With Schizophrenia and Their Primary Caregivers

NCT06563752

Schizophrenia

NOT_YET_RECRUITING NA

Efficacy of Repyflec Cognitive Remediation Group Training in Schizophrenia

NCT01279070

Indication for Modification of Patient Cognitive Status

COMPLETED PHASE4

Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation

NCT06361160

Treatment Resistant Schizophrenia

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective non-randomised feasibility trial will be performed. People with a diagnosis of treatment-resistant schizophrenia and their informal caregivers will test the digital mental health solution eMOTIPH for 6 months. Psychiatric treatment and psychological intervention (based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders; Farchione et al., 2012) will be delivered to patients.

The aim of the study is to evaluate the feasibility, acceptability, usability, satisfaction and perceived quality of life after using the eMOTIPH digital solution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A prospective non-randomised feasibility trial

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unified Protocol

The psychotherapy Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.

Group Type EXPERIMENTAL

eMotiph

Intervention Type DEVICE

Mobile application for patients with schizophrenia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eMotiph

Mobile application for patients with schizophrenia.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-55 years old.
* Diagnosis of schizophrenia following the Diagnostic and Statistical Manual of Mental Disorders-5 criteria.
* Meet criteria for treatment-resistant schizophrenia.
* Used to information and communication technology and with the physical capability to use them.

Exclusion Criteria

* Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005).
* The presence of delusions mainly related to their therapists or with new technologies.
* Hearing, vision or motor impairment that makes it impossible to operate a smartphone.
* Intellectual Developmental Disability.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No